ArticleOncogene2000
Bcl-2 accelerates multistep prostate carcinogenesis in vivo.
Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 43 citations in OpenAlex.
- Study on the molecular regulatory mechanism of MicroRNA-195 in the invasion and metastasis of colorectal carcinoma.International journal of clinical and experimental medicine · 2015Article
- Current mouse and cell models in prostate cancer research.Endocrine-related cancer · 2013Review
- Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.Cancer metastasis reviews · 2013Review
- Genetically engineered mouse models of prostate cancer.Molecular oncology · 2013Review
- Bcl-2 modulation to activate apoptosis in prostate cancer.Molecular cancer research : MCR · 2009Article
- Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres.BMC cancer · 2008Article
- X-linked inhibitor of apoptosis deficiency in the TRAMP mouse prostate cancer model.Cell death and differentiation · 2008Article
- The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells.Molecular endocrinology (Baltimore, Md.) · 2005Article
- A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells.Oncogene · 2004Article
- Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Hormone-refractory prostate cancer: a multi-step and multi-event process.Prostate cancer and prostatic diseases · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The impact of bcl-2 proto-oncogene expression on the pathogenesis and progression of prostate cancer was examined in a transgenic mouse model. Probasin-bcl-2 transgenic mice were crossed with TRAMP (TRansgenic Adenocarcinoma Mouse Prostate) mice that express the SV40 early genes (T/t antigens) under probasin control. Prostate size, cell proliferation, apoptosis, and the incidence and latency of tumor formation were evaluated. The double transgenic, probasin-bcl-2 X TRAMP F1 (BxT) mice exhibited an increase in the wet weight of the prostate. This was associated with an increase in proliferation, attributable to T/t antigens, and a decrease in apoptosis attributable to bcl-2. The latency to tumor formation was also decreased in the BxT mice compared to the TRAMP mice. The incidence of metastases was identical in both the TRAMP and BxT mice. Lastly, the incidence of hormone-independent prostate cancer was reduced in the BxT mice compared to the TRAMP mice. Together, these results demonstrate that bcl-2 can facilitate multistep prostate carcinogenesis in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.